


Ask a doctor about a prescription for Bupropion Neuraxpharm
Bupropion hydrochloride
Bupropion Neuraxpharm is a prescription-only medicine used to treat depression. It acts on chemicals in the brain called norepinephrineand dopamine.
If any of the above situations apply to the patient, they should contact their doctor immediately without taking Bupropion Neuraxpharm.
Before starting to take Bupropion Neuraxpharm, the patient should discuss it with their doctor or pharmacist.
Bupropion Neuraxpharm is not recommended for the treatment of children under 18 years of age.
In children under 18 years of age treated with antidepressants, there is an increased risk of
suicidal thoughts and behaviors.
In patients with depression, suicidal thoughts or self-harm behaviors may sometimes occur. Such behaviors may worsen when the patient first starts taking antidepressants, as it takes some time, usually about two weeks, but sometimes longer, for these medicines to start working.
Such thoughts may occur more frequently:
If the patient is currently taking or has taken within the last 14 days other antidepressants called monoamine oxidase inhibitors(MAOIs), they should contact their doctor without taking Bupropion Neuraxpharm(see also "When not to take Bupropion Neuraxpharm" in section 2).
including herbal medicines or vitamins, including those bought without a prescription. The doctor may change the dose of Bupropion Neuraxpharm, recommend a change in dosing, or discontinue other medicines being taken.
Some of them may increase the risk of seizures or convulsions. Other medicines may increase the risk of other side effects. Examples of such medicines are listed below, but this is not an exhaustive list.
If any of the above situations apply to the patient, they should contact their doctor immediately before starting to take Bupropion Neuraxpharm. The doctor will assess the risk and benefits of using Bupropion Neuraxpharm.
If any of the above situations apply to the patient, they should contact their doctor immediately before starting to take Bupropion Neuraxpharm.
Bupropion Neuraxpharm may reduce the effectiveness of certain medicines:
Alcohol may affect the action of Bupropion Neuraxpharm, and their concurrent use may, although rarely, cause nervousness or changes in mental state. Some patients become more sensitive to alcohol while taking Bupropion Neuraxpharm. The doctor may recommend abstaining from alcohol (beer, wine, vodka) or significantly reducing its consumption while taking Bupropion Neuraxpharm. If the patient is currently drinking large amounts of alcohol, they should not stop drinking suddenly, as this may cause a seizure.
The patient should discuss their alcohol consumption with their doctor before starting to take Bupropion Neuraxpharm.
Bupropion Neuraxpharm may affect the results of laboratory tests for the presence of other medicines.
If the patient is undergoing such a test, they should inform their doctor or nurse that they are taking Bupropion Neuraxpharm.
Bupropion Neuraxpharm should not be taken during pregnancy, if the patient is suspected to be pregnant, or if they plan to become pregnant, unless their doctor recommends otherwise. Before taking any medicine during pregnancy, the patient should consult their doctor or pharmacist. Some, but not all, studies suggest an increased risk of congenital defects, particularly heart defects, in children whose mothers took Bupropion Neuraxpharm. It is not known whether this was caused by the use of this medicine.
The ingredients of Bupropion Neuraxpharm may pass into breast milk. Before taking Bupropion Neuraxpharm, the patient should consult their doctor or pharmacist.
If Bupropion Neuraxpharm causes dizziness or a feeling of emptiness in the head, the patient should not drive or operate machinery.
This medicine should always be taken exactly as prescribed by the doctor or pharmacist. The doctor will recommend a dose individually for the patient. In case of doubts, the patient should consult their doctor or pharmacist.
Improvement in the patient's condition may occur only after some time. The full effect of the medicine may only become apparent after a few weeks or months. Even if the patient starts to feel better, their doctor may recommend continuing to take Bupropion Neuraxpharm to prevent a relapse of depression.
Bupropion Neuraxpharm is available in a dose of 300 mg. For a dose of 150 mg, the patient should use another suitable product available on the market.
Usually, the recommended dose for adults is one150 mg tablet once a day.
The doctor may recommend increasing the dose to 300 mg once a day if the patient does not improve after a few weeks of treatment.
The dose of Bupropion Neuraxpharm should be taken in the morning. The patient should not take Bupropion Neuraxpharm more than once a day.
The tablet is coated with a shell that slowly releases the medicine into the digestive tract. The patient may notice something in their stool that looks like a tablet. This is the empty shell that has been eliminated from the body.
Bupropion Neuraxpharm tablets should be swallowed whole. They should not be chewed, crushed, or divided – if this happens, there is a risk of overdose due to the rapid release of the medicine into the body. This may increase the risk of side effects, including seizures.
For some patients, a dose of 150 mg once a day is sufficient throughout the treatment period. The doctor may recommend this dosing if the patient has liver or kidney disease.
Only the doctor, together with the patient, can decide how long to take the treatment with Bupropion Neuraxpharm. It may take weeks or months before any improvement is observed. The patient should regularly consult their doctor to assess their depression symptoms, so that it can be decided how long they should be treated. If the patient feels better, their doctor may recommend continuing to take Bupropion Neuraxpharm to prevent a relapse of depression.
Taking too many tablets may cause seizures or convulsions. The patient should not delay and should contact their doctor or the nearest hospital emergency department immediately.
If the patient misses a dose, they should wait and take the next dose at the usual time. They should not take a double dose to make up for the missed dose.
The patient should not stop the treatment with Bupropion Neuraxpharm or reduce the dose without first discussing it with their doctor.
In case of any further doubts about the use of this medicine, the patient should consult their doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
About 1 in 1000 patients taking Bupropion Neuraxpharm may experience seizures (convulsions). The likelihood of this is higher in patients who take higher doses than recommended, take certain medicines, or are in a group with an increased risk of seizures. In case of doubts, the patient should contact their doctor.
If a seizure occurs, the patient should contact their doctor. They should not take Bupropion Neuraxpharm again.
Some patients may experience allergic reactions to Bupropion Neuraxpharm. These include:
Frequency not known - frequency cannot be estimated from the available data from patients taking Bupropion Neuraxpharm. Lupus is an immune system disorder that affects the skin and other organs. If the patient experiences worsening of lupus or a skin rash or skin changes (especially on skin areas exposed to sunlight) while taking Bupropion Neuraxpharm, they should contact their doctor immediately, as it may be necessary to stop the treatment.
Acute generalized exanthematous pustulosis (AGEP)
Frequency not known – frequency cannot be estimated from the available data from patients taking Bupropion Neuraxpharm.
Symptoms of AGEP include a rash with pus-filled blisters.
Very common side effects:may occur in more than 1 in 10 patients.
Other side effects have occurred in an unknown, though small, number of patients:
If the patient experiences any side effects, including any side effects not listed in the leaflet, they should tell their doctor or pharmacist.
Side effects can be reported directly to the Department of Adverse Reaction Monitoring of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, phone: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
By reporting side effects, it is possible to gather more information on the safety of the medicine.
The medicine should be stored out of sight and reach of children.
The patient should not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the month.
There are no special precautions for the storage of the medicinal product.
Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
The active substance of the medicine is bupropion hydrochloride. Each tablet contains 300 mg of bupropion hydrochloride (which corresponds to 260.40 mg of bupropion).
The other ingredients are:
Tablet core: povidone K 90, cysteine hydrochloride monohydrate, colloidal silica anhydrous, glycerol dibehenate, magnesium stearate.
Coating: ethylcellulose 100 mPas, povidone K 90, macrogol 1450, methacrylic acid and ethyl acrylate copolymer (1:1), 30% dispersion containing sodium lauryl sulfate and polysorbate 80, colloidal silica hydrated, triethyl citrate
Ink: shellac, iron oxide black (E 172), and propylene glycol.
Bupropion Neuraxpharm 300 mg tablets are cream-white to light yellow, round, with the imprint "GS2" in black on one side of the tablet, the other side is smooth. The diameter of the tablet is approximately 9.3 mm.
Blister: OPA/Aluminum/PVC/Aluminum blister containing 30 or 90 tablets, in a cardboard box.
Not all pack sizes may be marketed.
neuraxpharm Arzneimittel GmbH
Elisabeth-Selbert Strasse 23
40764 Langenfeld
Germany
neuraxpharm Arzneimittel GmbH
Elisabeth-Selbert Strasse 23
40764 Langenfeld
Germany
Neuraxpharm Pharmaceuticals, S.L.
Avda. de Barcelona, 69
08970 Sant Joan Despí, Barcelona
Spain
To obtain more detailed information, the patient should contact the representative of the marketing authorization holder
in Poland:
Neuraxpharm Polska sp. z o.o.
ul. Poleczki 35
02-822 Warszawa
[email protected]
Austria
Bupropion neuraxpharm 300 mg Tabletten mit veränderter Wirkstofffreisetzung
Czech Republic
Bupropion Neuraxpharm
Netherlands
Bupropion HCl Neuraxpharm 300 mg tabletten met gereguleerde afgifte
Germany
Bupropion-neuraxpharm 300 mg Tabletten mit veränderter Wirkstofffreisetzung
Poland
Bupropion Neuraxpharm
Slovakia
Bupropion 300 mg Tablety s riadeným uvoľňovaním
Date of last revision of the leaflet:
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for Bupropion Neuraxpharm – subject to medical assessment and local rules.